Aims and Scope of Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology is a peer-reviewed medical journal covering oncological pharmacotherapy. It was established in 1978 and is published by Springer Science+Business Media. The editors-in-chief are E.Chatelut (Paul Sabatier University) and E.A. Sausville (University of Maryland). It has been included in Index medicus (MEDLINE) since its first issue. According to the ISI 2016 Journal Citation Reports, the journal has an impact factor of 2.737, and its ranking was 98/254 (Pharmacology & Pharmacy) and 122/217 (Oncology). Less
Key Metrics
CiteScore 

5.9
Impact Factor 

< 5
SJR 

Q2Oncology

SNIP 

0.96
Recommended pre-submission checks
Powered by 

Topics Covered on Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1978 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cancer Chemotherapy and Pharmacology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Cancer Chemotherapy and Pharmacology
Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4.
- 6 Aug 2026
- Cancer chemotherapy and pharmacology
Drug repurposing as a promising therapeutic strategy against renal cell carcinoma.
- 21 Jul 2026
- Cancer chemotherapy and pharmacology
Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis.
- 20 Jul 2026
- Cancer chemotherapy and pharmacology
Red blood cell partitioning and the interpretation of palbociclib plasma concentrations - a letter to the editor.
- 20 Jul 2026
- Cancer chemotherapy and pharmacology
Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.
- 18 Jul 2026
- Cancer chemotherapy and pharmacology
Design characteristics of mass balance studies conducted for protein kinase inhibitors.
- 13 Jul 2026
- Cancer chemotherapy and pharmacology
Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4.
- 6 Aug 2026
- Cancer chemotherapy and pharmacology
Drug repurposing as a promising therapeutic strategy against renal cell carcinoma.
- 21 Jul 2026
- Cancer chemotherapy and pharmacology
Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis.
- 20 Jul 2026
- Cancer chemotherapy and pharmacology
Red blood cell partitioning and the interpretation of palbociclib plasma concentrations - a letter to the editor.
- 20 Jul 2026
- Cancer chemotherapy and pharmacology
Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.
- 18 Jul 2026
- Cancer chemotherapy and pharmacology
Design characteristics of mass balance studies conducted for protein kinase inhibitors.
- 13 Jul 2026
- Cancer chemotherapy and pharmacology